KALA
Kala Pharmaceuticals Inc
NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY
$0.11
-3.93% today
Updated 2026-04-30
Market cap
$110.98M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-3.31
Dividend yield
—
52W range
$0 – $21
Volume
9.1M
Kala Pharmaceuticals Inc (KALA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.84M | $-15.36M | $-15.09M | $-27.35M | $-34.10M | $-54.12M | $-92.72M | $-90.69M | $-108.23M | $-78.91M | $-27.93M | $-29.38M | $-31.99M |
| Capital expenditures | $789000.00 | $225000.00 | $252000.00 | $153000.00 | $480000.00 | $1.58M | $1.33M | $1.94M | $886000.00 | $313000.00 | $610000.00 | $208000.00 | $15000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | $638000.00 | $2.07M | $3.57M | $8.62M | $9.99M | $13.31M | $16.09M | $7.01M | $7.46M | $8.39M | $7.00M |
| Free cash flow | $-11.63M | $-15.59M | $-15.34M | $-27.50M | $-34.58M | $-55.70M | $-94.06M | $-92.64M | $-109.12M | $-79.22M | $-28.54M | $-29.59M | $-32.01M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $0.00 | — | — | — | — | — | $365000.00 | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $69.12M | $68.41M | $-85.07M | $-8.28M | — | — | — | — | — |